Vaxart Inc (VXRT)

$0.32 0.00 (N/A)
Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
170 Harbor Way, Suite 300, South San Francisco, United States
WALTERPAYTON34
WALTERPAYTON34 Nov. 15 at 12:00 AM
$VXRT jury trial appears to be finally set Two weeks 4-14-26 to 5-1-26
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Nov. 14 at 11:56 PM
$VXRT This chart looks amazingly but remember Cidara did a 1-20 reverse split 18 months ago which is the equivalent of an $11 per share stock price
1 · Reply
Elementary_Trader
Elementary_Trader Nov. 14 at 11:36 PM
$VXRT Listen to them discuss speeding up approvals and the trial requirements. P2b data should be monitored throughout the trial and results available along the way if FDA procedures are incorporated! 😖 Hurry it up. (You can watch easily at 1.5 speed) https://x.com/drmakaryfda/status/1989344379086196906?s=46&t=U2nEdV6p0oqjncd2eUqhSQ
0 · Reply
AnilDK79
AnilDK79 Nov. 14 at 11:35 PM
$VXRT cidara gets bought for $9.2B for flu prevention. great P2B results on 5K ppl at 60-76% efficacy depending on dose. tested for 6-7 months. good cross reactivity. they just started P3. they are injectable. Vaxart P2B should be a solid inflection point if all goes well. better platform, likely Noro partnership by then. i dont know that we need to wait 5 years or even 3 years
1 · Reply
amessagefromtheodd
amessagefromtheodd Nov. 14 at 10:30 PM
$VXRT I have to send Sean Tucker and Cummings and Lo an email, but really Sean, keep being to smart and they are gonna F around and move you…
1 · Reply
VXRT_Squirrel
VXRT_Squirrel Nov. 14 at 10:29 PM
$VXRT Something to think about.... $9.2 Billion for a "Flu Prevention Drug". (First time Squirrel has heard of such a thing.... has he been asleep at the wheel?) Nice to see BP still has some serious cash to throw around. https://www.statnews.com/2025/11/14/merck-acquire-cidara-therapeutics-influenza-prevention/?utm_campaign=pharmalot&utm_medium=email&_hsenc=p2ANqtz--Wnv9slFrlzIL_WGwoqQLVDQDOx3ys8dnZoTbHSUQAUG0KaNIBtcEF2_vRCKnKWDPrgT6Znu99Nq-jxV5FGACEzJlJgLj3d5JS7-XWjA84_5YeS1k&_hsmi=390027561&utm_content=390027561&utm_source=hs_email Have a nice weekend everyone. More gloomy weather ahead for us SF-Bay Area Folk.
0 · Reply
vigi
vigi Nov. 14 at 10:00 PM
$VXRT washington state update...(only seen in animals) https://abcnews.go.com/Health/suspected-human-bird-flu-case-1st-us-9/story?id=127519769
1 · Reply
NickG88
NickG88 Nov. 14 at 9:39 PM
$VXRT YOYO, I can make a wicked cup of COCOA... But HEY HEY where's that partnership for the NoROO!?
0 · Reply
Dave247
Dave247 Nov. 14 at 9:34 PM
$VXRT Lo is a used car salesman. Apologies for insulting any used car salesmen with that comparison.
1 · Reply
WALTERPAYTON34
WALTERPAYTON34 Nov. 14 at 9:33 PM
$VXRT why is Lo listed as Biotech and not CEO of Vaxart
3 · Reply
Latest News on VXRT
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:41 PM EST - 20 hours ago

Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

Vaxart to Host Upcoming Conference Calls

Nov 7, 2025, 8:00 AM EST - 7 days ago

Vaxart to Host Upcoming Conference Calls

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Nov 5, 2025, 4:01 PM EST - 9 days ago

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

DVAX

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Nov 5, 2025, 4:00 PM EST - 9 days ago

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

DVAX

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Oct 8, 2025, 8:00 AM EDT - 5 weeks ago

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Vaxart Appoints W. Mark Watson as Lead Independent Director

Sep 17, 2025, 4:05 PM EDT - 2 months ago

Vaxart Appoints W. Mark Watson as Lead Independent Director

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Sep 10, 2025, 4:54 PM EDT - 2 months ago

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Sep 10, 2025, 9:00 AM EDT - 2 months ago

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Vaxart Announces Adjournment of Special Meeting of Stockholders

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Vaxart Announces Adjournment of Special Meeting of Stockholders

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Sep 2, 2025, 4:30 PM EDT - 2 months ago

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Sep 2, 2025, 9:00 AM EDT - 2 months ago

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Aug 21, 2025, 9:30 AM EDT - 3 months ago

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:01 PM EDT - 3 months ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Aug 13, 2025, 5:25 PM EDT - 3 months ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Jul 24, 2025, 4:01 PM EDT - 4 months ago

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Jun 13, 2025, 4:52 PM EDT - 5 months ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Jun 11, 2025, 7:30 AM EDT - 5 months ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Jun 10, 2025, 4:47 PM EDT - 5 months ago

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Jun 2, 2025, 4:20 PM EDT - 5 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025, 4:05 PM EDT - 6 months ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025, 8:00 AM EDT - 6 months ago

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025, 8:00 AM EDT - 6 months ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025, 8:00 AM EDT - 6 months ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025, 5:00 PM EDT - 6 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025, 8:00 AM EDT - 6 months ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025, 8:00 AM EDT - 6 months ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14, 2025, 4:05 PM EDT - 6 months ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:43 PM EDT - 6 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 6 months ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 13, 2025, 4:01 PM EDT - 6 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 12, 2025, 8:00 AM EDT - 6 months ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

May 5, 2025, 8:00 AM EDT - 6 months ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

May 2, 2025, 8:00 AM EDT - 7 months ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Apr 30, 2025, 8:00 AM EDT - 7 months ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 7 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 7 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 6:25 PM EDT - 8 months ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 20, 2025, 4:01 PM EDT - 8 months ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Mar 5, 2025, 4:05 PM EST - 9 months ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Jan 13, 2025, 7:55 PM EST - 10 months ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Dec 2, 2024, 4:01 PM EST - 1 year ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:19 PM EST - 1 year ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:01 PM EST - 1 year ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Sep 30, 2024, 4:12 PM EDT - 1 year ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 15, 2024, 1:57 PM EDT - 1 year ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

WALTERPAYTON34
WALTERPAYTON34 Nov. 15 at 12:00 AM
$VXRT jury trial appears to be finally set Two weeks 4-14-26 to 5-1-26
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Nov. 14 at 11:56 PM
$VXRT This chart looks amazingly but remember Cidara did a 1-20 reverse split 18 months ago which is the equivalent of an $11 per share stock price
1 · Reply
Elementary_Trader
Elementary_Trader Nov. 14 at 11:36 PM
$VXRT Listen to them discuss speeding up approvals and the trial requirements. P2b data should be monitored throughout the trial and results available along the way if FDA procedures are incorporated! 😖 Hurry it up. (You can watch easily at 1.5 speed) https://x.com/drmakaryfda/status/1989344379086196906?s=46&t=U2nEdV6p0oqjncd2eUqhSQ
0 · Reply
AnilDK79
AnilDK79 Nov. 14 at 11:35 PM
$VXRT cidara gets bought for $9.2B for flu prevention. great P2B results on 5K ppl at 60-76% efficacy depending on dose. tested for 6-7 months. good cross reactivity. they just started P3. they are injectable. Vaxart P2B should be a solid inflection point if all goes well. better platform, likely Noro partnership by then. i dont know that we need to wait 5 years or even 3 years
1 · Reply
amessagefromtheodd
amessagefromtheodd Nov. 14 at 10:30 PM
$VXRT I have to send Sean Tucker and Cummings and Lo an email, but really Sean, keep being to smart and they are gonna F around and move you…
1 · Reply
VXRT_Squirrel
VXRT_Squirrel Nov. 14 at 10:29 PM
$VXRT Something to think about.... $9.2 Billion for a "Flu Prevention Drug". (First time Squirrel has heard of such a thing.... has he been asleep at the wheel?) Nice to see BP still has some serious cash to throw around. https://www.statnews.com/2025/11/14/merck-acquire-cidara-therapeutics-influenza-prevention/?utm_campaign=pharmalot&utm_medium=email&_hsenc=p2ANqtz--Wnv9slFrlzIL_WGwoqQLVDQDOx3ys8dnZoTbHSUQAUG0KaNIBtcEF2_vRCKnKWDPrgT6Znu99Nq-jxV5FGACEzJlJgLj3d5JS7-XWjA84_5YeS1k&_hsmi=390027561&utm_content=390027561&utm_source=hs_email Have a nice weekend everyone. More gloomy weather ahead for us SF-Bay Area Folk.
0 · Reply
vigi
vigi Nov. 14 at 10:00 PM
$VXRT washington state update...(only seen in animals) https://abcnews.go.com/Health/suspected-human-bird-flu-case-1st-us-9/story?id=127519769
1 · Reply
NickG88
NickG88 Nov. 14 at 9:39 PM
$VXRT YOYO, I can make a wicked cup of COCOA... But HEY HEY where's that partnership for the NoROO!?
0 · Reply
Dave247
Dave247 Nov. 14 at 9:34 PM
$VXRT Lo is a used car salesman. Apologies for insulting any used car salesmen with that comparison.
1 · Reply
WALTERPAYTON34
WALTERPAYTON34 Nov. 14 at 9:33 PM
$VXRT why is Lo listed as Biotech and not CEO of Vaxart
3 · Reply
ndouglas48
ndouglas48 Nov. 14 at 9:28 PM
$VXRT Chart looks great. Didn't get the weekly candle I "wanted" but still got a great finish. The bottom has been tested and the coming weeks/months/years are going to be great. I don't share the view that many others have here in wanting a buyout or acquisition. This may be THE greatest "life-changing" tech in the next decade and many are just getting impatient. And this is coming from someone who has experienced the heartache of the last 5 years.... This is a 3-5+ years hold. Let them do what they need to do and enjoy the ride. Giving up now is like quitting in mile 25 of a marathon.
1 · Reply
Fatio
Fatio Nov. 14 at 9:21 PM
$VXRT Lo liked the Merck deal news . In linked in .
1 · Reply
VXRT_lurker
VXRT_lurker Nov. 14 at 9:02 PM
$VXRT closing in the .40’s feels huge for this week.
0 · Reply
Fishingcash
Fishingcash Nov. 14 at 8:54 PM
$VXRT No power hour on OTC??
0 · Reply
amessagefromtheodd
amessagefromtheodd Nov. 14 at 8:51 PM
$VXRT I’ll tell ya what, Vaxart don’t have much more space if any to be tickering around with constructs, and talking a lot…
0 · Reply
BrutisWalter
BrutisWalter Nov. 14 at 8:50 PM
$VXRT CAN'T You just see Lo making another Friday AH PR so the SP is unaffected on Monday! I JUST HAVE A FEELING.
0 · Reply
Glass_Lo
Glass_Lo Nov. 14 at 8:13 PM
$VXRT Sold one of my high buys for Tax loss🤷🏻‍♂️ We’ll see where we are in 30 days…Or I’ll just buy in my other account if we hit the $.20’s.
0 · Reply
DOC1977
DOC1977 Nov. 14 at 8:00 PM
$VXRT again with the fuckin .40 bs , who tf is holding this down ….. let it go already !!!!!
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Nov. 14 at 7:54 PM
$VXRT should breakout to mid 50’s or more on increased volume
0 · Reply
Joe_Mussia
Joe_Mussia Nov. 14 at 7:47 PM
$VXRT I know some people have buyer's remorse about the RS. Last month, SENS, did a 1-for-20 reverse stock split. The company reported a strong preliminary third-quarter revenue of $8.1 million, a 91% increase year-over-year, driven by a 160% rise in new U.S. patients. Here is their chart over that time period -
1 · Reply
LuckyLee
LuckyLee Nov. 14 at 7:42 PM
$VXRT Let's Go Vaxart 💥 Power Hour..!
0 · Reply
Essegi
Essegi Nov. 14 at 7:38 PM
$VXRT noooooo nooooooo stay up ….
0 · Reply